A report from the “Credit Suisse” Center confirms the ability of the “Sputnik-V” vaccine to fight the Corona virus

A report prepared by the Swiss Center “Credit Suisse” confirmed that the method adopted to produce the Russian vaccine “Sputnik-V” against Corona increases its effectiveness and ensures its ability to overcome problems related to immunity.

The report was released after discussions about the third phase of clinical trials of the vaccine, between representatives of the Russian center “Gamalia” and a team of analysts from “Credit Suisse”, one of Switzerland’s financial conglomerates.

Analysts at the center pointed out that the approach taken by the Russian Gamalia Center to produce the “Sputnik-V” vaccine is similar to that used by the “J&J” and “CanSino” centers for vaccine development, and the center s ‘is based on adenoviral vectors.

The center explained that the main difference that distinguishes the Sputnik vaccine from its analogues is the reliance on two different adenovirus vectors for the first (rAd5) and second (rAd26) dose of the vaccine, which overcomes potential problems. that may be in the immune system.

Source: Novosti

Follow RT on